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ABSTRACT 
The aim of present study was to prepare the mouth disintegrating combination tablet of ranitidine Hcl and domperidone by using different 
concentration of superdisintegrants. The tablet were prepared using mannitolas diluent, sodium saccharin as sweetner, potato starch as binder, 
magnesium stearate as lubricant,avicel as filler or bulking agents along with three different levels of disintegrant. The superdisintegrants used 
inthis study are crosprovidone and sodium starch glycolate. The pre-compression evaluation of powder was done such as angle of repose, bulk 
density, tapped density, carr’scompressibility index and hausner ratio. After compression of tablet post compression evaluation were done like 
thickness, hardness, weight variation, friability, wetting time, water absorption ratio, disintegration time (DT) and dissolution study. From the 
obtained results, it can be concluded that the tablet formulation prepared with sodium starch glycolate 50 mg showed disintegrating time of 30 
seconds with drug release of 97.17±1.1, 88.82±0.6% of ranitidine hydrochloride and domperidone respectively after 30 minute and the 
hardness, friability, dissolution rate of prepared tablets (batch F3) were found to be acceptable according to standard limits 
Keywords: Ranitidine Hcl (R-Hcl), Domperidone (DOM), Sodium starch glycolate (SSG), Crossprovidone, Mouth disintegrating tablet (MDT), 
Direct compression. 
 
Article Info: Received 05 June 2019;     Review Completed 24 July 2019;     Accepted 02 Aug 2019;     Available online 15 August 2019 
Cite this article as: 
Suradkar SR, Ambekar AW, Formulatiom, Preparation and Evaluation of Mouth Disintegrating Tablet of Ranitidine HCl 
and Domperidone, Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):497-504     
http://dx.doi.org/10.22270/jddt.v9i4-s.3360                                                           
*Address for Correspondence:  
Suradkar Shivaji Rambhau, Department of Pharmaceutics, Dr. V.V. P.F’s College of Pharmacy, Vilad Ghat PO MIDC; Ahmednagar - 414111 (MS) 
India. 
 
 
INTRODUCTION: 
The oral routes of drug administration have wide acceptance 
that will be up to 50-60% of total dosage forms. Solid dosage 
forms are the most popular because of the easy 
administration, accurate dosage, self-medication, pain 
avoidance and most important are the patient compliance. 
US Food and Drug Administration Center for Drug Evaluation 
and Research (CDER) defines, in the ‘Orange Book’, an MDT 
as “a solid dosage form containing medicinal substances, 
which disintegrates rapidly, usually within a matter of 
seconds, when placed upon the tongue”. The technologies 
used for manufacturing fast-dissolving tablets are direct 
compression method, freeze-drying, spray-drying, tablet 
molding, Sublimation, sugar-based excipients, tablet 
compression, and disintegration addition 1. 
The formulation was done by using R-Hcl and DOM as an API 
with different concentration of superdisintegrant such as 
SSG, Crossprovidone. R-Hcl is antacid which used to reduce 
the gastric acidity. The gastric acidity resulting duo to 
increasing the pH level of stomach and duodenum. The 
gastric acidity occur duo to the excessive secretion of acid in 
stomach. DOM is antiemetic drug which used to control or to 
prevent vomiting and nausea. Omitting occurs duo to the 
stimulations of emetic center such as Chemoreceptor trigger 
zone (CTZ) 2,3. 
MATERIAL AND METHODS: 
Materials 
R-Hcl and DOM were obtained as gift sample by Ajanta 
pharma, Aurangabad and Rajesh pharma, Mumbai, india 
along with their working standard. Sodium starch glycolate 
(SSG), Crosprovidone, Sodium starch, and Arosil (Ozone 
international Pvt, Ltd.). Menthol and potao starch from 
Rajesh pharma, Mumbai, india.All the other chemicals used 
were of suitable analytical grade. 
Methods 
The given amounts of complex equivalent drug was taken 
and passed through sieve no.80# and then mixed with 
directly compressible diluent (mannitol) and 
superdisintegrants (Crosspovidone, Sodium Starch 
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Glyconate) in a mortar.  Magnesium  stearate,  Aerosil,  
saccharin sodium, were passed through sieve no. 60#, than 
crash the menthol into powder than mixed and blended with 
initial mixture and mix it 10min in the mortar followed by 
compression of the blend using, a single punch multistation 
compression machine, which is equipped with 12 mm 
concave edge punches. The formula is showed in table no.1. 
Pre-compression parameter: 
Angle of repose: 
The flow ability of powder was determined by calculating 
angle of repose by using funnel method. The funnel with 10 
mm internal diameter of stem was fixed at a height of 2 cm 
over the platform. About 20 gm of sample was slowly passed 
along the wall of the funnel till the tip of the pile formed and 
touches the stem of the funnel. A rough circle was drawn 
around the pile base and the radius of the powder cone was 
measured. Angle of repose was calculated from the average 
radius using the following formula; 4 
Ɵ = tan-1(h/r) 
Where,  
θ = Angle of repose 
h = Height of the pile 
r = Average radius of the powder cone 
Bulk density (Db): 
It is the ratio of total mass of powder to the bulk volume of 
powder. It was measured by pouring the weight powder 
(passed through sieve # 20) into a measuring cylinder and 
initial weight was noted. This initial volume is called the bulk 
volume. From this the bulk density is calculated according to 
the formula mentioned below. It is expressed in gm/ml and 
calculated by formula as given 5,6. 
                     
                      
                              
 
Tapped density (Dt): 
It  is  the  ratio  of  total  mass  of  the  powder  to  the  tapped  
volume  of  the  powder.  Volume was measured by tapping 
the powder for 100 times and the tapped volume was noted. 
Then, if the difference between these two volumes is less 
than 2%. If  it  is  more  than  2%,  then  tapping  is continued  
for  some  times  and  tapped  volume  was  noted.  Tapping  
was  continued  until  the difference  between  successive  
volumes  is  less  than  2%  (in  a  burette  density  
apparatus).  It is expressed in gm/ml and given by formula as 
given 5,6. 
                                                   Dt = M / Vt 
Where, M - is the weight of sample in grams, Vt- is the 
volume occupied by the sample. 
Compressibility index or Carr’s index: 
The simplest method of measurement of flow powder is 
compressibility, an indication of the ease with which 
material can be induced to flow is given by compressibility 
index (I). Compressibility Index is indirect measurement of 
bulk density, size shape, and surface area, moisture content 
& cohesive of material because all of these can influence the 
observed compressibility index. The compressibility index is 
calculated as follows 7. 
                      
                           
              
 
 
Hausners ratio: 
Hausner ratio is an indirect index of ease of powder flow. It is 
calculated by the following formula.   Lower Hausner’s ratio 
(<1.25) indicates better flow properties than higher ones 
(>1.25) 8. 
               
             
            
 
Table 1: Formulation table of Mouth Disintegrating Tablets 
Sr. 
No. 
Ingredients Quantity in (mg) 
F1 F2 F3 F4 F5 F6 
1. Ranitidine Hcl 150 150 150 150 150 150 
2. Domperidone 30 30 30 30 30 30 
3. Sodium Starch 
Glyconate 
40 - 50 - 60 - 
4. Crosprovidone - 60 - 60 - 60 
5. Sodium Saccharin 30 30 30 30 30 30 
6. Mannitol 50 50 40 40 30 30 
7. Potato Starch 15.71 15.71 15.71 15.71 15.71 15.71 
8. Avicel102 164.30 164.30 164.30 164.30 164.30 164.30 
9. Aerosil 10 10 10 10 10 10 
10. Menthol 5 5 5 5 5 5 
11. Magnesium stearate 5 5 5 5 5 5 
 
Total weight (mg) 
 
500 
 
500 
 
500 
 
500 
 
500 
 
500 
 
Post Compression Parameter: 
General appearance: 
The general appearance is the physical appearance of tablet. 
It has two aspects, first one is the patient compliance, if the 
tablet appearance is legible and good. It also help to improve 
the patient compliance. The second one is for the 
manufacturer; it helps him in the trouble free 
manufacturing, if there is tablet to tablet, batch to batch and 
lot to lot uniformity of tablet.General appearance would 
include a number of aspects like, size, shape, odor, taste, 
texture, legibility, and identifying marks 8. 
Thickness: 
The thickness  of  individual  tablets  was  measured  using  
vernier caliper,  which  permits  the accurate  measurements 
of the thickness and diameter and also provides  information  
of  the  variation  between tablet to tablets.  Tablets 
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thickness should be controlled within ± 5% variation of a 
standard value 8. 
Hardness: 
The hardness of six tablets was measured by Monsanto 
hardness tester. Hardness of tablets was measured in terms 
of kg/cm2 8. 
Weight variation: 
Weight variation test is accomplished to check that the 
manufactured tablets have a uniform weight. As per USP, the 
twenty tablets are weighed separately and an compendia 
weight is taken, the mean weight is obtained, by dividing the 
compendia weight by 20, now the average weight is 
compared to the individual weight of the tablet, For a tablet 
to pass the test not more than 2 tablets should lie out of the 
specified percentage and if no tablet fault by more than two 
times the percentage limit 9. 
Friability: 
Friability is the test for a tablet to see whether the tablet is 
stable to abrasion or not, it is tested by using Roche 
friabilator. This is made up of a plastic drum fixed with a 
machine which rotated at 25 rpm for 100 revolutions. Then 
the twenty tablets which were weighed prior to the test are 
taken out of the drum and cleaned with a cloth and weighed 
once again, the weight variation must not be less than 0.5 to 
1.0 % for a conventional tablet 10,11. 
                
                         
            
 
Wetting Time: 
The wetting time of dosage form is related to the contact 
angle of tablet this method was used to measure tablet 
wetting time. A piece of tissue paper folded twice, it was 
placed in a small petri dish of 6.5 cm in diameter containing 
10 ml of pH 7.4 buffer, a tablet was put on the paper, and the 
time for complete tablet wetting was measured 12. 
Water absorption ratio: 
The water absorption ratios of the tablet were carried out in 
petri dishes with tablet. it was determined using phosphate 
buffer pH 7.4. Periodically, the tablets were withdrawn from 
the petri dishes and weighed on electronic balance after 
removal of surface water by light blotting with a lab tissue 
for change of their weight till a constant weight is attained, 
tablet was weighed and it was carefully placed on the paper 
at room temperature (wb). The wetted tablet was reweighed 
(Wa).  Water absorption ratio R, was then determined 
according to the following equation,12 
 
  
     
  
 
Where, 
Wb and Wa are the weight before and after absorption, 
respectively. 
In vitro disintegration time: 
For a drug to be absorbed from a solid dosage form after oral 
administration, it must first be in solution, and the first 
important step toward this condition is usually the break-up 
of the tablet; a process known as disintegration. 
The in-vitro disintegration time of a tablet was determined 
using disintegration test apparatus. It is determined by using 
disintegration device which consist of 6 glass tubes that are 
3 inches long. Open at one end and held against 10 mesh 
screen at the bottom end of basket rack assembly. To test for 
disintegration time, one tablet is placed in each tube.  All 
tablets must disintegrate and particles must pass through 
the 10 mesh in the time specified. In which to prepare the 
phosphate buffer pH 7.4, 900ml was used as disintegration 
medium, and to maintain the temperature at 37±0.20C. The 
time was measure in second for complete disintegration of 
the tablet with there was no palpable mass glass tube 13. 
In vitro Dissolution study: 
Dissolution profiles of R-Hcl & DOM tablets were determined 
using the USP Type-II apparatus with paddle speed at 50 
rpm. Dissolution was performed in 900 ml pH 7.4 phosphate 
buffer solution at 37±0.5C.  2ml  of  samples  were  
withdrawn  at  5,  10,  15,  20,  25,  30 minutes time intervals. 
The volume of dissolution fluid was adjusted to 900 ml, by 
replacing each 2ml aliquot, aliquot were filtered through 
Whatman filter paper (no.41), further diluted to 10ml using 
phosphate buffer pH7.4 solution and analyzed at 314 nm& 
291 nm respectively. Using UV-Visible double beam 
spectrophotometer (JASCO V-630) 12,13. 
Drug content: 
An accurately weighed amount of complex (equivalent to 10 
mg of R-Hcl and DOM) was dissolved in small volume of 
Phosphate buffer PH 7.4 in volumetric flask and made up to 
the volume .From this solution 5,10, 15, 20, 25,30 ppm 
concentration are prepared in 10 ml volumetric flask and 
made up to the volume. The solution was filtered; the 
absorbance of this solution was measured at 314 nm and 
291 nm respectively, using appropriate blank.12’13 
RESULTS AND DISCUSSION 
 
Figure 1: UV spectrum of R-Hcl 
Table 2: Analytical data for calibration Curve of R-Hcl: 
Concentration Absorbance at 314nm 
2 0.1837±0.04 
4 0.2705±0.05 
6 0.386±0.06 
8 0.4998±0.01 
10 0.5896±0.02 
12 0.7201±0.02 
All values are mean ±SD (n=3)
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Figure 2: Calibration curve of R-Hcl. 
 
Figure 3: UV spectrum of DOM 
Table 3. Analytical data for calibration curve of DOM: 
Concentration Absorbance at 291nm 
2 0.079±0.01 
4 0.187±0.04 
6 0.289±0.03 
8 0.422±0.04 
10 0.554±0.05 
12 0.672±0.04 
All values are mean ±SD (n=3) 
.  
Figure 4: Calibration curve of DOM.
A) R-Hcl: 
 
Figure 5: IR Spectrum of R-Hcl. 
B) DOM:  
 
Fifure 6: IR spectrum of DOM. 
C) R-Hcl + DOM + excipient: 
 
Fifure7: IR spectrum of R-Hcl + DOM + excipient: 
y = 0.075x + 0.0527 
R² = 0.9978 
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Figure8: DSC graph of R-Hcl. 
 
Figure 9: DSC graph of DOM. 
 
 
Figure 10: DSC graph Formulation F3. 
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Table 4: Characterization of Blends Powder. 
 
Formulations 
Angle of repose 
(Ɵ) 
Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Carr’s index 
(%) 
Hausner’s 
ratio 
F1 22.780 ± 0.02 0.49 ± 0.05 0.58 ±0.01 15.51 ±0.01 1.18 ±0.01 
F2 21.800 ±0.10 0.51 ±0.01 0.57 ±0.01 14.03 ±0.02 1.16 ±0.02 
F3 24.560  ± 0.03 0.58 ±0.01 0.66 ±0.01 12.00 ±0.02 0.87 ±0.02 
F4 23.740  ±0.05 0.47 ±0.011 0.55 ±0.05 14.50 ±0.04 1.17±0.011 
F5 22.290  ±0.09 0.56 ±0.057 0.67 ±0.05 13.98 ±0.01 1.18±0.012 
F6 29.800  ±0.05 0.48 ±0.12  0.56 ±0.05 14.28 ±0.02 1.16 ±0.01 
       All values are mean ±SD (n=3) 
Table 5: Evaluation of formulated tablets. 
Sr. 
No. 
Formulation Hardness 
(kg/cm2) 
Thickness 
(mm) 
Weight 
variation 
Friability 
(%) 
1. F1 3.6 ±0.05 2.0 ±0.1 0.92 ±0.011 0.53  ±0.01 
2. F2 3.5 ±0.15 2.1 ±0.05 0.74 ±0.01 0.79  ±0.02 
3. F3 3.5 ±0.15 2.0 ±0 1.24 ±0.01 0.67  ±0.01 
4. F4 3.9 ±0.2 2.2 ±01 1.52 ±0.02 0.72  ±0.011 
5. F5 3.6 ±0.05 2.1 ±0.05 1.70 ±0.05  0.63  ±0.015 
6. F6 3.7 ±0.11 2.1 ±0.05 0.97 ±0.02  0.68  ±0.017 
                All values are mean ±SD (n=3) 
Table 6: Evaluation of formulated tablets. 
Sr. 
no 
Formulation Diameter 
(mm) SD 
Wetting 
Time(sec) 
Water 
Absorption ratio 
Disintegration 
Time (sec) 
1. F1 12 ±0.3 40 ±1 28.4 ±0.2 35±2 
2. F2 12 ±0.4 50 ±1.5 36.8 ±0.3 50 ±2 
3. F3 12 ±0.2 36 ±1 22.0 ±0.1 30 ±1 
4. F4 12 ±0.1 55 ±0.5 37.4 ±0.20 40 ±1.34 
5. F5 12 ±0.3 44 ±1.6 24.2 ±0.20 35 ±0.58 
6. F6 12 ±0.4 61 ±2.5 35.6 ±0.6 42 ±1.50 
               All values are mean ±SD (n=3) 
 
 
Figure 11:% Drug release profile of R-Hcl. 
Table 7: % Drug release of R-Hcl. 
TIME 
(min) 
F1 F2 F3 F4 F5 F6 
0 00 00 00 00 00 00 
5 21.57±2.2 13.40±2.8 27.78±3.0 14.18±2.2 34.13±1.9 14.80±2.1 
10 35.96±3.1 35.00±2.5 43.23±2.2 21.96±2.0 40.50±2.9 24.37±2.4 
15 65.00±1.9 48.27±2.3 66.18±2.1 43.96±2.4 67.20±2.0 43.29±2.5 
20 72.51±2.9 65.62±2.9 80.94±2.9 63.01±2.6 72.66±2.1 63.10±3.2 
25 80.93±2.2 71.72±3.1 86.38±2.8 74.78±2.9 84.16±2.2 74.22±2.1 
30 93.04±2.1 83.38±2.2 97.17±2.1 83.78±3.2 94.80±2.5 85.32±2.2 
              All values are mean ±SD (n=3)  
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Figure 12: % Drug release profile of DOM. 
Table 8 : % Drug release of DOM. 
Time 
(min) 
F1 F2 F3 F4 F5 F6 
0 00 00 00 00 00 00 
5 09.54±2.1 08.26±2.2 11.24±1.9 09.54±2.0 14.34±2.1 11.23±2.0 
10 23.5±2.2 15.67±2.5 26.96±2.1 17.70±2.3 30.68±2.5 17.96±2.3 
15 31.68±2.3 34.00±3.1 50.46±2.2 39.88±2.6 55.64±2.3 34.26±2.6 
20 55.70±3.1 46.40±2.6 64.24±2.6 46.52±2.8 69.34±3.0 45.09±2.5 
25 69.24±2.5 53.12±3.0 76.98±2.3 62.32±1.6 77.22±2.6 62.62±2.4 
30 80.04±2.9 69.08±2.1 88.92±3.6 77.54±2.2 84.90±3.1 83.42±2.9 
 
Table 9: % Drug release and % drug content 
Sr. 
No. 
Formulation % Drug Release % Drug content 
R-Hcl. DOM R-Hcl. DOM 
1. F1 93.04±2.1 80.04±2.9 98.92±3.0 93.99±2.2 
2. F2 83.38±3.2 69.08±2.1 97.98±2.9 93.56±2.1 
3. F3 97.17±2.4 88.82±3.6 99.90±2.9 97.89±3.1 
4. F4 83.78±3.2 77.54±2.2 99.87±3.2 94.52±2.6 
5. F5 94.80±2.5 84.90±3.1 98.91±3.1 95.91±3.1 
6. F6 85.32±4.0 83.42±2.9 99.05±3.2 94.97±1.2 
               All values are mean ±SD (n=3)  
DISCUSSION: 
In the present study first compatibility studies with various 
excipients and API was found to be compatible with all the 
excipients, study was done by FTIR and DSC.Then various 
Pre-compression parameters like bulk density, tapped 
density, Hausner’s ratio, Carr’s consolidation index and angle 
of repose were determined and found to be within the limits 
and post compression parameters like hardness, thickness, 
weight variation, friability, wetting time, water absorption 
ratio were determined and found to be within range. The 
disintegration time of all the formulation is 30-50 second and 
In-vitro dissolution of all the formulations were analyzed and 
among all the six formulations, F3 shown maximum drug 
release of 97.17±2.4, 88.82± 3.6% of ranitidine 
hydrochloride and domperidone respectively after 30 
minute.  
CONCLUSION: 
Fast dissolving drug delivery will be used widely in the 
coming years to impart better patient compliance. Since 
mouth disintegrating tablet is useful in enhancing drug 
disintegration and dissolution within seconds, it becomes 
popular. In addition, they will become a solution for patients 
who have difficulty swallowing and need rapid onset of 
action. In this study formulation of mouth disintegrating 
tablet using ranitidine hydrochloride, domperidone as API 
with using sodium starch glycolate and crossprovidone as 
superdisintegrant. Formulation F3 is optimized formulations, 
it show good precompression and postcompression 
parameter. It shows good hardness, friability and 
disintegrating time, drug content and dissolution study. It 
disintegrates within 30 second with 97.17±2.4% and 
88.82±3.6 % drug release of R-Hcl and DOM respectively. 
Thus it can be concluded that mouth disintegrating tablet of 
R-Hcl and DOM can be prepared using SSG (sodium starch 
glycolate) as superdisintegrating agent which can be used in 
emergency with no need of water. 
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